Select Your Region

Abbiamo rilevato che stai visitando questa pagina da United States. Seleziona la tua regione preferita per continuare.

vai al contenuto

Selezione paese

In base alla tua posizione

Europe

North America

Latin America

Asia-Pacific

Verifica del settore sanitario

Questa sezione contiene informazioni destinate agli operatori sanitari.

Si prega di confermare di far parte di un’azienda operante nel settore sanitario.

Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays

Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.

Pubblicato: 13/11/2026 | Modificato: 13/11/2026

Sebia has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the FLC Kappa & Lambda assays.

These are the first EIA tests receiving 510(k) from the FDA for the quantitative detection of both kappa and lambda free light chains (FLC) in human serum specimens, intended for both aid of diagnosis and monitoring of #Multiple Myeloma and Immunoglobulin Light-Chain (AL-) amyloidosis.

As a global leader for multiple myeloma testing, Sebia expands its offer in the U.S. with this new solution, easily adaptable to automated immunoassay instruments for a high throughput processing. The ELISA format overcomes main challenges in analytical performance often seen in alternative testing methods
Arnaud Collin Sebia Group Vice President Global Regulatory Affairs & Quality

Test associated with this resource